ACM
KURA icon

Alethea Capital Management’s Kura Oncology KURA Stock Holding History

Alethea Capital Management’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-150,000
Closed -$278K – 23
2025
Q3 		$278K Buy
+150,000
New +$1.07M 0.18% 28

Other funds holding KURA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Alethea Capital Management's KURA Position: Q1 2026 in Review

Alethea Capital Management increased its Kura Oncology (KURA) stake by 7.5% in Q1 2026, buying an estimated $917K and bringing the position to 1,529,369 shares worth $12.4M. The position accounts for 6.38% of the portfolio, ranked #3.

Alethea Capital Management first reported a position in KURA in Q2 2016 and has held it in 37 quarters since. The position peaked at $14.8M in Q4 2025. 220 funds tracked by Wall St. Rank hold KURA as of Q1 2026.

  • Alethea Capital Management held 1,529,369 shares of Kura Oncology worth $12.4M as of Q1 2026.
  • Alethea Capital Management bought 106,687 Kura Oncology shares in Q1 2026, an estimated $917K.
  • Kura Oncology made up 6.38% of Alethea Capital Management's portfolio in Q1 2026, its #3 holding.
  • Alethea Capital Management first reported a position in Kura Oncology in Q2 2016 and has held it in 37 quarters since.
  • Alethea Capital Management's Kura Oncology position peaked at $14.8M in Q4 2025.
  • 220 funds tracked by Wall St. Rank held Kura Oncology as of Q1 2026.

Based on Alethea Capital Management's 13F filing for Q1 2026, filed 13 May 2026.